MELI vs CL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MELI · MercadoLibre$1,510.00 ▼ 1.33%
CL · Colgate-Palmolive$96.56 ▼ 2.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MELI -27.8%
- CL +25.3%
Head to head
| Metric | MELI | CL |
|---|---|---|
| Price | $1,510.00 | $96.56 |
| Change today | ▼ 1.33% | ▼ 2.16% |
| Market cap | $76.55B | $76.76B |
| Return, 3 months | -17.2% | +3.7% |
| Return, year to date | -25.0% | +24.4% |
| Return, 1 year | -28.4% | +24.8% |
| P/E (TTM) | 40.5 | 37.6 |
| P/B | 9.3 | 266.7 |
| P/E percentile vs own 5y | 4th | 85th |
| Dividend yield | – | 2.17% |
| Revenue growth (YoY, latest qtr) | +49.8% | +4.6% |
| Net profit growth (YoY) | -10.9% | +1.7% |
| Gross margin | 42.7% | 60.6% |
| Operating margin | 8.3% | 19.2% |
| Net margin | 5.3% | 9.6% |
| Return on equity | 27.5% | 358.9% |
| Analyst target vs. price | +51.8% | +7.0% |
| Analyst buy share | 91% | 80% |
| RSI (14) | 31 | 59 |
| 30-day volatility | 57.7% | 28.2% |
| Max drawdown, 1 year | -36.0% | -17.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CL is the largest of the group by market value.
- CL has returned the most over the past year.
- CL carries the lowest trailing P/E.
- MELI is growing revenue fastest.
- CL keeps the most profit per dollar of sales.
- CL has been the calmest stock over the last 30 days.